Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
110.53
-0.46 (-0.41%)
At close: Jan 9, 2026, 4:00 PM EST
110.63
+0.10 (0.09%)
After-hours: Jan 9, 2026, 7:58 PM EST
Merck & Co. Revenue
Merck & Co. had revenue of $17.28B in the quarter ending September 30, 2025, with 3.72% growth. This brings the company's revenue in the last twelve months to $64.24B, up 1.68% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$64.24B
Revenue Growth
+1.68%
P/S Ratio
4.32
Revenue / Employee
$856,467
Employees
75,000
Market Cap
274.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
| Dec 31, 2019 | 39.12B | -3.17B | -7.50% |
| Dec 31, 2018 | 42.29B | 2.17B | 5.41% |
| Dec 31, 2017 | 40.12B | 315.00M | 0.79% |
| Dec 31, 2016 | 39.81B | 309.00M | 0.78% |
| Dec 31, 2015 | 39.50B | -2.74B | -6.48% |
| Dec 31, 2014 | 42.24B | -1.80B | -4.08% |
| Dec 31, 2013 | 44.03B | -3.23B | -6.84% |
| Dec 31, 2012 | 47.27B | -780.00M | -1.62% |
| Dec 31, 2011 | 48.05B | 2.06B | 4.48% |
| Dec 31, 2010 | 45.99B | 18.56B | 67.66% |
| Dec 31, 2009 | 27.43B | 3.58B | 15.00% |
| Dec 31, 2008 | 23.85B | -347.70M | -1.44% |
| Dec 31, 2007 | 24.20B | 13.60B | 128.41% |
| Dec 31, 2006 | 10.59B | 1.09B | 11.42% |
| Dec 31, 2005 | 9.51B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
MRK News
- 12 hours ago - Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion - WSJ
- 14 hours ago - Healthy Returns: What to expect from pharma at the JPM conference - CNBC
- 1 day ago - Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list - Reuters
- 1 day ago - Merck in talks to buy biotech Revolution Medicines, FT reports - Reuters
- 1 day ago - Merck: Fundamentals Amplified By A Momentum Breakout - Seeking Alpha
- 2 days ago - Merck could lose up to $630 million in revenue after CDC changes HPV vaccine recommendation - Market Watch
- 2 days ago - Vaxxas Appoints Former Merck Global Vaccines President David Peacock as CEO - GlobeNewsWire
- 2 days ago - Quant Q&A With Steven Cress - Seeking Alpha